Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity

A functionalized nanohydrogel siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from previous cell line studies that knockdown of EGFR (epidermal growth factor receptor) may be of clinical significance in the treatment of epithelial tumors especially with...

Descripción completa

Detalles Bibliográficos
Autores principales: Satpathy, Minati, Mezencev, Roman, Wang, Lijuan, McDonald, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098171/
https://www.ncbi.nlm.nih.gov/pubmed/27819259
http://dx.doi.org/10.1038/srep36518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098171/
https://www.ncbi.nlm.nih.gov/pubmed/27819259
http://dx.doi.org/10.1038/srep36518

Ejemplares similares